AADI

Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update

Retrieved on: 
Wednesday, March 6, 2024

LOS ANGELES, March 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024 at 8:30 am ET (5:30 am PT) to report fourth quarter and full-year 2023 financial results and provide recent corporate updates.

Key Points: 
  • Company to Host Conference Call and Webcast on March 13, 2024
    LOS ANGELES, March 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024 at 8:30 am ET (5:30 am PT) to report fourth quarter and full-year 2023 financial results and provide recent corporate updates.
  • Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com .
  • To participate via telephone, please register in advance here: Conference Registration (vevent.com) .
  • A replay of the conference call and webcast will be archived on the website for at least 30 days.

Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference

Retrieved on: 
Monday, February 26, 2024

LOS ANGELES, Feb. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, announced today its presentation at the TD Cowen 44th Annual Healthcare Conference, taking place March 4-6, 2024, in Boston.

Key Points: 
  • LOS ANGELES, Feb. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, announced today its presentation at the TD Cowen 44th Annual Healthcare Conference, taking place March 4-6, 2024, in Boston.
  • Dave Lennon, Ph.D., President and CEO, will present a company overview on Monday, March 4, 2024, from 2:10 PM – 2:40 PM ET.
  • The presentation will be webcast live on the IR pages of the Aadi Bioscience website and will be available for replay for approximately 30 days following each investor event.

Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Retrieved on: 
Thursday, December 14, 2023

LOS ANGELES, Dec. 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today reported results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations. 

Key Points: 
  • "Our tumor agnostic PRECISION1 trial is designed to elucidate the impact of nab-sirolimus on cancers expressing inactivating alterations of TSC1 or TSC2, regardless of tumor type.
  • Nine different tumor types were enrolled in the TSC1 arm and 13 tumor types were enrolled in the TSC2 arm.
  • 80 patients are currently enrolled in the PRECISION1 trial, supporting the two-thirds interim analysis expected in the third quarter of 2024.
  • The Aadi management team is hosting a conference call and webcast today at 5:00 pm ET (2:00 pm PT) to discuss the interim results from the PRECISION1 trial.

Aadi Bioscience to Participate in Jefferies London Healthcare Conference

Retrieved on: 
Monday, November 6, 2023

LOS ANGELES, Nov. 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation in the Jefferies London Healthcare Conference, taking place November 14-16, 2023, in London.

Key Points: 
  • LOS ANGELES, Nov. 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation in the Jefferies London Healthcare Conference, taking place November 14-16, 2023, in London.
  • Dave Lennon, Ph.D., President and CEO, will participate in a fireside chat on Tuesday, November 14, 2023, at 8:30 am GMT.
  • The fireside chat will be webcast live on the IR pages of the Aadi Bioscience website and will be available for replay for approximately 30 days following each investor event.

Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update

Retrieved on: 
Wednesday, November 1, 2023

LOS ANGELES, Nov. 1, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023 at 8:30 am ET (5:30 am PT) to report third quarter 2023 financial results and provide an operational update.

Key Points: 
  • Company to Host Conference Call and Webcast on Wednesday, November 8, 2023
    LOS ANGELES, Nov. 1, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023 at 8:30 am ET (5:30 am PT) to report third quarter 2023 financial results and provide an operational update.
  • Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com .
  • To participate via telephone, please register in advance at this link .
  • A replay of the conference call and webcast will be archived on the Company's website for at least 30 days.

Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Retrieved on: 
Tuesday, October 3, 2023

The award was granted pursuant to the terms of Dr. Lennon's employment agreement and as a material inducement to his joining Aadi as President and Chief Executive Officer in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The award was granted pursuant to the terms of Dr. Lennon's employment agreement and as a material inducement to his joining Aadi as President and Chief Executive Officer in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Compensation Committee of Aadi's Board of Directors, which is composed entirely of independent directors, approved, as a material inducement to Dr. Lennon entering into employment with Aadi, a grant of a nonstatutory stock option to purchase 490,000 shares of Aadi's common stock (the "Option") under the Plan.
  • The Option has a 10-year term and an exercise price per share equal to $4.30, the closing price as quoted on the Nasdaq Stock Market LLC on the Grant Date.
  • In addition, the Option may be subject to vesting acceleration upon certain qualifying termination events in accordance with the terms and conditions set forth in Dr. Lennon's employment agreement with Aadi.

Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer

Retrieved on: 
Monday, October 2, 2023

LOS ANGELES, Oct. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies with mTOR pathway alterations, today announced the appointment of Dave Lennon, Ph.D. as President and Chief Executive Officer.  Dr. Lennon brings more than twenty years of experience leading global biotechnology and pharmaceutical teams, with significant expertise in development and commercialization in oncology and non-oncology mTOR-driven diseases.  Dr. Lennon has also joined the Aadi Bioscience Board of Directors.  In connection with Dr. Lennon's appointment, Scott Giacobello, who served as Interim Chief Executive Officer and President since March 2023, will continue in his role as Chief Financial Officer. 

Key Points: 
  • Dr. Lennon has also joined the Aadi Bioscience Board of Directors.
  • In connection with Dr. Lennon's appointment, Scott Giacobello, who served as Interim Chief Executive Officer and President since March 2023, will continue in his role as Chief Financial Officer.
  • "Dave brings tremendous experience to Aadi.
  • Dr. Lennon joins Aadi Bioscience following his role as Chief Executive Officer and member of the board of directors at Satellite Bio, a privately held regenerative medicine company.

Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, September 20, 2023

LOS ANGELES, Sept. 20, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that four abstracts have been selected for presentation at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, MA.

Key Points: 
  • LOS ANGELES, Sept. 20, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that four abstracts have been selected for presentation at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, MA.
  • The presentations include four posters: a Trials-in-Progress (TiP) update from the PRECISION1 trial in TSC1/2 alterations, two real-world clinical genomic analyses, and one preclinical study of nab-sirolimus combinations in breast cancer xenograft models.
  • Title: "Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient (pt) population using the Foundation Medicine genomic database"

Aadi Bioscience to Participate at Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 5, 2023

Scott Giacobello, Interim CEO and President and CFO of Aadi, will present in-person on Tuesday, September 12, 2023, at 12:00 pm ET.

Key Points: 
  • Scott Giacobello, Interim CEO and President and CFO of Aadi, will present in-person on Tuesday, September 12, 2023, at 12:00 pm ET.
  • Morgan Stanley 21st Annual Global Healthcare Conference – The conference will take place September 11-13, 2023, in New York City.
  • Mr. Giacobello will participate in an in-person fireside chat on Wednesday, September 13, 2023, at 9:30 am ET.
  • The presentation and fireside chat will be webcast live on the IR pages of the Aadi Bioscience website and will be available for replay for approximately 30 days following each investor event.

Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update

Retrieved on: 
Wednesday, August 9, 2023

LOS ANGELES, Aug. 9, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2023.

Key Points: 
  • LOS ANGELES, Aug. 9, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2023.
  • FYARRO net product sales were $6.2 million in the second quarter, reflecting growth of approximately 6% over Q1 2023 and 80% over the prior year quarter.
  • The Aadi management team is hosting a conference call and webcast today at 8:30 am ET (5:30 am PT) to provide a corporate update and discuss results for the second quarter 2023.
  • Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com .